MEDICINOVA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 USD | -3.18% |
|
-5.59% | -10.00% |
Presenter SpeechUnknown Analyst (Analysts)Okay, hi, good afternoon. We're here with MediciNova...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.394
USD
Average target price
17
USD
Spread / Average Target
+1,119.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 68.39M | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- MNOV Stock
- News MediciNova, Inc.
- Transcript : MediciNova Inc. Presents at Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov-14-2012 03
